Unique Ingredient Identifier K0KQV10C35 is listed as a ingredient substance
RN | 9003-39-8 |
NCIT | C82259 |
RXCUI | 1367141 |
MF | Polymer substance not supported |
UNII K0KQV10C35 POVIDONE K25 is commonly included in medications in the following forms.
Route | Dosage Form | Potency |
---|---|---|
ORAL | CAPSULE | 30 mg |
ORAL | CAPSULE, EXTENDED RELEASE | 21.36 MG |
ORAL | CAPSULE, SUSTAINED ACTION | 17.79 MG |
ORAL | CAPSULE, SUSTAINED ACTION, HARD GELATIN | 12.6 MG |
ORAL | GRANULE, FOR ORAL SUSPENSION | 0.27 MG |
ORAL | SOLUTION | 500 MG/5ML |
ORAL | SUSPENSION, SUSTAINED ACTION | 0.27 MG/206.84 MG |
ORAL | TABLET | 52 MG |
ORAL | TABLET (IMMED./COMP. RELEASE), FILM COATED | 54.47 MG |
ORAL | TABLET, CHEWABLE | 0.45 MG |
ORAL | TABLET, COATED | 40 MG |
ORAL | TABLET, DELAYED ACTION | 12.3 MG |
ORAL | TABLET, DELAYED ACTION, ENTERIC COATED | 20 MG |
ORAL | TABLET, EXTENDED RELEASE | 5 MG |
ORAL | TABLET, FILM COATED | 22.5 MG |
ORAL | TABLET, MULTILAYER, EXTENDED RELEASE | 1.8 MG |
ORAL | TABLET, SUSTAINED ACTION, COATED | NA |